OptimizeRx Launches AI-Powered Real-World Evidence Solution on Its Point-of-Care Platform
The new enhancement involves the application of advanced analytics, using machine-learning methods applied to real-world data (RWD), resulting in the accurate delivery of therapeutic support and brand messages to clinicians at critical points in a patient's care journey.
This use of patient and scenario modeling that optimizes and automates information delivery at the point-of-care is unprecedented in the industry.
The solution creates new opportunities for life science organizations to better support providers as they look to make the best treatment decisions for their patients, especially for those with complex dosing requirements or chronic disease indications. The innovation also enables more messages to be delivered to more physicians whose actions were not previously visible on the platform.
"Everyone is trying to solve the problem of siloed health data," noted
A recent analysis by the
“The entire healthcare system is focused on data interoperability in order to deliver the most effective care,” said
For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.
Tel (248) 651-6568 x807
Tel (754) 245-7070
Investor Relations Contact
CMA Investor Relations
Tel (949) 432-7557
Source: OptimizeRx Corporation